Uveal melanoma-associated survival in Scotland

• Published in: Eye (London) 2019-11, Vol.33 (11), p.1699-1706
• Main Authors: Jamison, Aaron, Bhatti, Lesley A., Sobti, Manvi M., Chadha, Vikas, Cauchi, Paul, Kemp, Ewan G.
• Format: Article
• Language: English
• Subjects: 631/67/1484; 692/699/3161/3177; 692/699/67/1484; Accreditation; Adolescent; Adult; Aged; Aged, 80 and over; Cancer; Cause of Death; Choroid Neoplasms - mortality; Ciliary Body - pathology; Death; Female; Humans; Iris; Iris Neoplasms - mortality; Laboratory Medicine; Male; Medical education; Medical Oncology - statistics & numerical data; Medicine; Medicine & Public Health; Melanoma; Melanoma - mortality; Middle Aged; Oncology; Ophthalmology; Patients; Pharmaceutical Sciences/Technology; Pharmaceuticals; Retrospective Studies; Scotland - epidemiology; Surgery; Surgical Oncology; Survival; Survival Rate; Uveal Neoplasms - mortality
• ISSN: 0950-222X; 1476-5454
• DOI: 10.1038/s41433-019-0622-9

Learning Objectives Upon completion of this activity, participants will be able to: Describe recorded cause of death and long-term melanoma-specific survival of patients with UM, according to an analysis of SOOS data Determine long-term cancer-specific and all-cause survival of patients with UM, according to an analysis of SOOS data Identify clinical implications of long-term all-cause and cause-specific survival of patients with UM, according to an analysis of SOOS data Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit Hours 1.0 Release date: 25 October 2019 Expiration date: 25 October 2020 Post-test link : https://medscape.org/eye/posttest918527 Authors/Editors disclosure information S.S. has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Optos; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. A.J., L.B., M.S., V.C., P.C., and E.K. have disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay has disclosed no relevant financial relationships. Background/Objectives The Scottish Ocular Oncology Service (SOOS) manages all patients with uveal melanoma (UM) in Scotland. Our aim was to determine the long-term all-cause and cause-specific survival of patients with UM, irrespective of treatment modality. Subjects/Methods A retrospective single-centre cohort study including all patients diagnosed with UM by the SOOS between 1/1/1998 and 31/12/2002. Data from the SOOS database were correlated with death records held by National Records of Scotla